v. Acknowledgement
None
Vi Impact statement
Key Message:
Oral immunotherapy is a promising and safe option for patients with cashew nut allergies, showing in our retrospective analysis a moderate rate of side effects of 33% and good feasibility with no dropouts because of taste aversion or adverse reactions.
Vii References
1. McWilliam V, Koplin J, Lodge C, Tang M, Dharmage S, Allen K. The Prevalence of Tree Nut Allergy: A Systematic Review. Curr Allergy Asthma Rep . 2015;15(9):54. doi:10.1007/s11882-015-0555-8
2. Mendes C, Costa J, Vicente AA, Oliveira MBPP, Mafra I. Cashew Nut Allergy: Clinical Relevance and Allergen Characterisation. Clin Rev Allergy Immunol . 2019;57(1):1-22. doi:10.1007/s12016-016-8580-5
3. Elizur A, Appel MY, Nachshon L, et al. NUT Co Reactivity - ACquiring Knowledge for Elimination Recommendations (NUT CRACKER) study.Allergy . 2018;73(3):593-601. doi:10.1111/all.13353
4. Grabenhenrich LB, Dölle S, Moneret-Vautrin A, et al. Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. J Allergy Clin Immunol . 2016;137(4):1128-1137.e1. doi:10.1016/j.jaci.2015.11.015
5. Clark AT, Anagnostou K, Ewan PW. Cashew nut causes more severe reactions than peanut: case-matched comparison in 141 children.Allergy . 2007;62(8):913-916. doi:10.1111/j.1398-9995.2007.01447.x
6. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol . 2010;125(6):1322-1326. doi:10.1016/j.jaci.2010.03.029
7. Brough HA, Caubet JC, Mazon A, et al. Defining challenge-proven coexistent nut and sesame seed allergy: A prospective multicenter European study. J Allergy Clin Immunol . 2020;145(4):1231-1239. doi:10.1016/j.jaci.2019.09.036
8. Dölle-Bierke S, Höfer V, Francuzik W, et al. Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry. J Allergy Clin Immunol Pract . Published online March 2023:S2213219823003124. doi:10.1016/j.jaip.2023.03.026
9. Fleischer DM, Conover-Walker MK, Matsui EC, Wood RA. The natural history of tree nut allergy. J Allergy Clin Immunol . 2005;116(5):1087-1093. doi:10.1016/j.jaci.2005.09.002
10. Peters RL, Guarnieri I, Tang MLK, et al. The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study. J Allergy Clin Immunol . 2022;150(3):657-665.e13. doi:10.1016/j.jaci.2022.04.008
11. Baumert JL, Taylor SL, Koppelman SJ. Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy. J Allergy Clin Immunol Pract . 2018;6(2):457-465.e4. doi:10.1016/j.jaip.2017.05.006
12. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med . 2018;379(21):1991-2001. doi:10.1056/NEJMoa1812856
13. Silva D, Rodríguez Del Río P, Jong NW, et al. Allergen immunotherapy and/or biologicals for IgE‐mediated food allergy: A systematic review and meta‐analysis. Allergy . 2022;77(6):1852-1862. doi:10.1111/all.15211
14. Loke P, Hsiao KC, Lozinsky A, et al. Probiotic and Peanut OIT Leads to Long-Lasting Sustained Unresponsiveness and Quality-of-Life Improvement in Peanut-Allergic Children . Preprints; 2021. doi:10.22541/au.162769428.85138587/v1
15. Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. The Lancet . 2022;399(10322):359-371. doi:10.1016/S0140-6736(21)02390-4
16. Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy . 2018;73(4):799-815. doi:10.1111/all.13319
17. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. The Lancet . 2019;393(10187):2222-2232. doi:10.1016/S0140-6736(19)30420-9
18. Elizur A, Appel MY, Nachshon L, et al. Cashew oral immunotherapy for desensitizing cashew‐pistachio allergy (NUT CRACKER study).Allergy . 2022;77(6):1863-1872. doi:10.1111/all.15212
19. Erdle SC, Cook VE, Cameron SB, et al. Real-World Safety Analysis of Preschool Tree Nut Oral Immunotherapy. J Allergy Clin Immunol Pract . 2023;11(4):1177-1183. doi:10.1016/j.jaip.2023.01.031
20. Sampson HA, Gerth Van Wijk R, Bindslev-Jensen C, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology–European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol . 2012;130(6):1260-1274. doi:10.1016/j.jaci.2012.10.017
21. Fernández‐Rivas M, Gómez García I, Gonzalo‐Fernández A, et al. Development and validation of the food allergy severity score.Allergy . 2022;77(5):1545-1558. doi:10.1111/all.15165
22. R Core Team. R: A language and environment for statistical computing. Published online 2022. https://www.R-project.org
23. Nachshon L, Schwartz N, Levy MB, et al. Factors associated with home epinephrine-treated reactions during peanut and tree-nut oral immunotherapy. Ann Allergy Asthma Immunol . 2023;130(3):340-346.e5. doi:10.1016/j.anai.2022.12.001
24. Guarnieri KM, Slack IF, Gadoury-Lévesque V, Eapen AA, Andorf S, Lierl MB. Peanut oral immunotherapy in a pediatric allergy clinic: Patient factors associated with clinical outcomes. Ann Allergy Asthma Immunol . 2021;127(2):214-222.e4. doi:10.1016/j.anai.2021.04.003
25. Blackman AC, Staggers KA, Anagnostou A. Anaphylaxis during Peanut Oral Immunotherapy: Looking beyond dose escalation. Pediatr Allergy Immunol . 2022;33(12). doi:10.1111/pai.13888
26. Nachshon L, Schwartz N, Tsviban L, et al. Patient Characteristics and Risk Factors for Home Epinephrine-Treated Reactions During Oral Immunotherapy for Food Allergy. J Allergy Clin Immunol Pract . 2021;9(1):185-192.e3. doi:10.1016/j.jaip.2020.07.034
27. Virkud YV, Burks AW, Steele PH, et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol . 2017;139(3):882-888.e5. doi:10.1016/j.jaci.2016.07.030
28. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol . 2009;124(2):292-300.e97. doi:10.1016/j.jaci.2009.05.022
29. Barshow SM, Kulis MD, Burks AW, Kim EH. Mechanisms of oral immunotherapy. Clin Exp Allergy . 2021;51(4):527-535. doi:10.1111/cea.13824
30. Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.J Allergy Clin Immunol . 2014;133(2):468-475.e6. doi:10.1016/j.jaci.2013.11.007
Viii Tables
TABLE 1. Baseline patient characteristics